F. Hoffmann-La Roche Ltd. manufactures pharmaceutical products. It offers pharmaceutical drugs, pharmaceutical instruments, and diagnostics solutions. The company was founded by Fritz Hoffmann-La Roche on October 1, 1896 and is headquartered in Basel, Switzerland.

Sanofi Genzyme is the specialty care global business unit of Sanofi, focused on rare diseases, multiple sclerosis, immunology, and oncology. They help people with debilitating and complex conditions that are often difficult to diagnose and treat. They are dedicated to discovering and advancing new therapies, providing hope to patients and their families around the world. Genzyme became part of Sanofi in 2011. While continuing to focus on rare diseases, they also established ourselves as a leader in the field of multiple sclerosis. In 2016, their focus expanded to include Sanofi’s programs in oncology and immunology. Their approach is shaped by a long history of developing highly specialized treatments and forging close relationships with physician and patient communities. Founded as Genzyme in Boston in 1981, they rapidly grew to become one of the world’s leading biotechnology companies, recognized for their pioneering development of treatments for rare genetic disorders and their innovative contributions to medical science and biomanufacturing.

Chugai Pharmaceutical Co., Ltd. engages in the research, development, manufacturing, sale, importation, and exportation of pharmaceuticals. Its operations are carried out through the Domestic and Overseas businesses. The Domestic Business covers the manufacturing, research, and development operations in Japan. The Overseas business comprises of sales and production in Europe, Taiwan and China. The company was founded by Juzo Ueno on March 10, 1925 and is headquartered in Tokyo, Japan.

Genentech is a biotechnology company that discovers, develops, manufactures, and commercializes medicines to treat patients with serious or life-threatening medical conditions. It creates multiple products on the market and a development pipeline. The company became a member of the Roche Group in 2009. As part of their merger agreement, Roche and Genentech combined their pharmaceutical operations in the United States. Genentech’s South San Francisco campus now serves as the headquarters for Roche pharmaceutical operations in the United States. Genentech’s Research and Early Development section operates as an independent center within Roche. Genentech was founded in 1976 by [Robert Swanson](https://www.crunchbase.com/person/robert-a-swanson) and [Herbert Boyer](https://www.crunchbase.com/person/herbert-w-boyer). It is headquartered in South San Francisco, C.A.

Sekisui Medical Co., Ltd., part of Sekisui Chemical Co., Ltd., is a company headquartered in Tokyo, Japan, that manufactures and markets in-vitro diagnostic substances and pharmaceutical products. Sekisui Chemical Co., Ltd. acquired Sekisui Medical Co., Ltd. from Daiichi Sankyo Co., Ltd. on October 02, 2006.

Beijing Xinaijin Biotechnology Co., Ltd., established on 2014-08-06, Business scope includes biological,Technical development of scientific research instruments and meters,technical consulting,Technical Services,technology transfer;Sales instrumentation,electronic product,chemical reagent(Items without administrative license);Import and export,Technology Import and Export.(Enterprises independently choose operating projects according to law,Carry out business activities;Items subject to approval by law,Carry out business activities in accordance with the approved content after approval by relevant departments;Do not engage in the business activities of projects prohibited and restricted by the city's industrial policies.)

Regeneron Pharmaceuticals is a biopharmaceutical company that discovers, develops, and commercializes pharmaceutical products for the treatment of serious medical conditions. The Company has therapeutic candidates in clinical trials for the potential treatment of cancer, eye diseases, and inflammatory diseases, and has preclinical programs in other diseases and disorders. The company’s product portfolio includes EYLEA, an aflibercept injection; ARCALYST, a rilonacept Injection for subcutaneous use; ZALTRAP for metastatic colorectal cancer; trap fusion proteins; and fully human monoclonal antibodies. On March 26, 2012, it was announced that Sanofi and Regeneron are in development with a new cholesterol drug which will help reduce cholesterol up to 72%. Regeneron Pharmaceuticals was founded in 1988 and is currently headquartered in New York, USA.

Shenyang Sunshine Pharmaceutical Co., Ltd. engages in the development and production of biological products. It offers recombinant human erythropoietin, interferon alfa 2b, interleukin 2, and thrombopoietin injections. Its business activities include research and development, and manufacture of biochemical reagents, and pharmaceutical project investment advisory services. The company was founded on January 3, 1993 and is headquartered in Shenyang, China.

Hangzhou Yisheng Pharmaceutical Technology Development Co., Ltd., established on 2021-03-18, Business scope includes general items:Technical Services,technology development,technical consulting,Technology Exchange,technology transfer,Technology Promotion;software sales;software development;Wholesale of computer software, hardware and auxiliary equipment;Retailing of computer software, hardware and auxiliary equipment;Experimental analysis instrument sales;Conference and Exhibition Services;Sales of Class II Medical Devices;Sales of Class I Medical Devices;Production of Class I Medical Devices;Production of protective equipment for medical personnel(Ι class medical device);Retailing of protective equipment for healthcare workers;Cosmetics Retail;Personal Hygiene Sales;Chemical product sales(No licensed chemical products);Chemical product production(No licensed chemical products)(Except for projects subject to approval by law,Carry out business activities independently in accordance with the law with a business license).

ACROBiosystems Co., Ltd. engages in the development of biomedicine and bio-protein technology. Its products include fluorescent label protein, immune-checkpoint protein, and cytokine. The company was founded on July 22, 2010 and is headquartered in Beijing, China.

Sanyou Biopharmaceuticals Co., Ltd. is a company headquartered in China that develops and manufactures antibody drugs.\nThe company says this about itself: Sanyou Biopharmaceuticals Co., Ltd. is a biological high-tech enterprise focusing on R&D and services of innovative antibody drugs. Sanyou is committed to establishing an internationally leading high-quality, high-throughput, integrated R&D and value transformation platform for innovative antibody drugs, constructing a business ecosystem involving therapy, R&D, and diagnostic products and services, and cooperating with global biopharmaceutical, diagnostic, and drug R&D companies to make a new progress in the diagnosis and treatment of human diseases. Sanyou has established an integrated innovative antibody drug R&D laboratory of over 20,000 square meters with advanced facilities and equipment, and more than 40 core innovation technology platforms, including platforms for innovative antibody drug discovery featured with a series of trillion-level phage display antibody libraries, innovative antibody drug optimization, cell line construction, upstream and downstream process development, preclinical R&D and industrial development.

Amador Biomedcine Hangzhou Co., Ltd., a subsidiary of Amador Bioscience, Inc, is a Chinese company located in Zhejiang. The firm provides laboratory, clinical research, strategic consulting and regulatory filing services for pharmaceutical companies. It was founded in 2018.

Merrimack Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company. engages in discovering, developing, and commercializing medicines consisting of novel therapeutics paired with diagnostics for the treatment of cancer. Its pipeline includes MM-131, MM-141, and MM-310. The company was founded by Anthony J. Sinskey, Gavin MacBeath, and Ulrik B. Nielsen in 1993 and is headquartered in Cambridge, MA.

Shanghai Zhijiang Biotechnology Co., Ltd. (688317.OC) was established in 2005. As a high-tech enterprise specializing in the research and development, production, and sales of genetic diagnostic reagents and instruments and equipment, it is one of the leading companies in the production of molecular diagnostic reagents in China. The rapid real-time fluorescent PCR diagnostic test reagents developed by the company are mainly used in clinical medicine, public health emergencies, entry-exit inspection and quarantine, food inspection, animal husbandry, aquaculture, and other fields. The company has established two 100,000-level and two 10,000-level production workshops and passed the ISO 13485 system demonstration, and at the same time passed the national SFDA in vitro diagnostic reagent quality management assessment, so that the company has the qualifications for medical device production license and medical device business license.

Dr. Reddy's Laboratories Ltd. engages in the manufacture and marketing of pharmaceutical products. It operates through the following segments: Global Generics, Pharmaceutical Services & Active Ingredients, Proprietary Products, and Others. The Global Generics segment consists of manufacturing and marketing of prescription and over-the-counter finished pharmaceutical products ready for consumption by the patient, marketed under a brand name or as generic finished dosages with therapeutic equivalence to branded formulations. The Pharmaceutical Services & Active Ingredients segment is comprised of manufacturing and marketing of active pharmaceutical ingredients and intermediates, also known as API, which are the principal ingredients for finished pharmaceutical products. The Proprietary Products segment focuses on research and development of differentiated formulations. The Others segment includes the operations of the subsidiary of the company. The company was founded by Kallam Anji Reddy on February 24, 1984 and is headquartered in Hyderabad, India.

Huzhou Zhongke Huxing Biotechnology Co., Ltd., established on 2019-02-18, The scope of business includes the research of medical biotechnology products,to develop,Sales and technical consulting services;cosmetic,Health products,Technical research on pharmaceutical raw materials,Development and technology transfer and technology consulting services;First,Second-class medical device sales and technical consulting services.(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments)

Atonomics A/S provides diagnostic equipment for the biotechnology industries. Its product Atolyzer, is a microscopic biosensor that applies surface acoustic waves in the measurement of low levels of biomarkers in biological samples. The firm develops products for the benefit of health care professionals and patients. The company was founded by Thomas Warthoe, Peter Warthoe and Lars Bangsgaard on October 5, 2000 and is headquartered in Copenhagen, Denmark.

Pneumagen focuses on developing glycan targeted carbohydrate-binding modules (CBMs) as a new universal therapeutic modality for the treatment of respiratory tract infections (RTIs) and cancer. Founded in 2016, the Company is a spin-out from the University of St Andrews in Scotland and has access to world-class scientific expertise and capabilities in glycobiology.

Boditech Med, Inc. engages in the provision of in-vitro diagnostics analyzers and reagents. Its products include cardiac, tumor, diabetes, hormone, infection, and rheumatoid arthritics tests. The company was founded on November 13, 1998 and is headquartered in Chuncheon-si, South Korea.